J. Lee

发表

Hormonal therapy and chemotherapy for advanced prostate cancer

J. Lee, 2015 .

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma

S. Signoretti, T. Choueiri, L. Ottesen, 2020, JAMA oncology.

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures

H. Go, I. Park, Y. Shim, 2019, BMC Urology.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

C. Porta, T. Choueiri, A. Hansen, 2019, European urology oncology.

A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non–clear‐cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus

I. Park, J. Lee, S. Lee, 2018, Clinical genitourinary cancer.

Conventional Cisplatin-Based Combination Chemotherapy Is Effective in the Treatment of Metastatic Spermatocytic Seminoma with Extensive Rhabdomyosarcomatous Transformation

J. Cheon, Doo-Ho Lim, J. Hong, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.

T. Ciuleanu, B. Alekseev, S. Pal, 2022, European urology.

Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.

T. Choueiri, S. Srinivas, B. Rini, 2020, European urology.

Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

T. Choueiri, G. De Velasco, C. Kollmannsberger, 2016, Cancer.

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

T. Choueiri, A. Kapoor, S. Pal, 2022, JAMA network open.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.

T. Choueiri, N. Agarwal, S. Srinivas, 2014, European urology.

Use of Gemcitabine Plus Carboplatin Is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4–5

Shinkyo Yoon, I. Park, Hyung-Don Kim, 2021, Cancer research and treatment.

A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component

Shinkyo Yoon, I. Park, H. Lee, 2019, Investigational New Drugs.

Discontinuing VEGF‐targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second‐line Therapies in Metastatic Renal Cell Carcinoma

J. Brugarolas, T. Choueiri, N. Agarwal, 2017, Clinical genitourinary cancer.

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

Y. Cho, Yeon-mi Ryu, Hyung-Don Kim, 2022, Frontiers in Oncology.

Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).

H. Lim, Shinkyo Yoon, K. Lee, 2020, European journal of cancer.

Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer.

Jin-Hee Ahn, I. Jeong, D. You, 2015, Clinical genitourinary cancer.

Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma

T. Powles, G. Sonpavde, C. Sternberg, 2022, European Journal of Cancer.

Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.

Shinkyo Yoon, I. Park, J. Lee, 2019, Clinical genitourinary cancer.

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

T. Powles, R. Motzer, T. Choueiri, 2016, The Lancet. Oncology.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Nicholas J. Vogelzang, Jingsong Zhang, Michael Ong, 2017, JAMA oncology.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

R. Motzer, J. Larkin, T. Choueiri, 2019, The New England journal of medicine.

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Amber C. Donahue, X. Mu, R. Motzer, 2020, Nature Medicine.

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Amber C. Donahue, X. Mu, R. Motzer, 2020, Nature Medicine.

Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients

Kwonoh Park, B. Keam, Shinkyo Yoon, 2021, Annals of laboratory medicine.

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

C. Porta, T. Choueiri, G. De Velasco, 2021, JAMA network open.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

C. Porta, A. Ravaud, R. Motzer, 2019, The Lancet.

Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.

S. Signoretti, T. Choueiri, L. Ottesen, 2022, European journal of cancer.

Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology

S. Park, J. Jo, Kwonoh Park, 2017 .

Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease

H. Kim, J. Lee, Jung Su Lee, 2013, Cancer research and treatment : official journal of Korean Cancer Association.

Korean guidelines for the management of metastatic prostate cancer

Young Seok Kim, S. Park, Kwonoh Park, 2021 .

Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options

I. Park, J. Lee, 2020, The Korean journal of internal medicine.

Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD‐1 or PD‐L1 inhibitor

Shinkyo Yoon, I. Park, J. Lee, 2021, Asia-Pacific journal of clinical oncology.

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

T. Choueiri, G. De Velasco, B. Tran, 2021, Cancer medicine.

Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma

Su-Jin Shin, Y. Cho, H. Go, 2020, Journal of Korean medical science.

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

T. Choueiri, A. Pantuck, S. Srinivas, 2015, European urology.

Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features

I. Park, J. Lee, Jwa Hoon Kim, 2016, Cancer Chemotherapy and Pharmacology.

Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.

D. Ye, Wen‐Cheng Chang, S. Pang, 2014, Clinical genitourinary cancer.

Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

T. Choueiri, N. Agarwal, S. Srinivas, 2017, European urology.

Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)

J. Brugarolas, T. Choueiri, B. Rini, 2017, Kidney cancer.

Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma.

Myung-Hwan Kim, D. Park, D. Seo, 2014, European journal of cancer.

Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma

I. Jeong, D. You, H. Ahn, 2015, Cancer Chemotherapy and Pharmacology.

Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma

H. Ahn, Cheryn Song, B. Hong, 2016, Cancer Chemotherapy and Pharmacology.

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

R. Motzer, T. Powles, T. Choueiri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

B. Keam, Shinkyo Yoon, Dalyong Kim, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.

R. Motzer, P. Russo, T. Choueiri, 2021, European urology.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma

E. V. Van Allen, S. Signoretti, R. Motzer, 2018, Cancer Immunology Research.

Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.

R. Berger, M. Carducci, M. Eisenberger, 2016, The oncologist.

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery

Shinkyo Yoon, Hyung-Don Kim, K. Park, 2021, Cancer research and treatment.

Inflammatory Myofibroblastic Tumor Showing Durable Remission after Anthracycline-Containing Cytotoxic Chemotherapy: Report of a Case

J. H. Park, C. Suh, Dalyong Kim, 2012 .

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

S. Signoretti, A. Hakimi, T. Choueiri, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.